WASHINGTON – The US Food & Drug Administration warns consumers not to purchase or use Skin-Cap aerosol spray products because they may contain undisclosed steroids.
This product, sold by Chemigroup France, formerly known as Cheminova Laboratories, is available on skincap.com, amazon.com, and walmart.com. It is marketed as a treatment for psoriasis, seborrheic dermatitis, typical eczema, painful lichen, skin redness, dandruff, itching, and irritation of the skin.
FDA testing identified a high-potency glucocorticosteroid (immunosuppressive and anti-inflammatory drug) in Skin-Cap aerosol spray products not disclosed on the label or packaging.
Consumers using this product should contact their healthcare professionals to determine the best course of action. Abruptly stopping the use of this product may cause adverse reactions.
Additionally, long-term use of topical corticosteroids, like glucocorticosteroids, can cause health problems such as skin thinning (atrophy) and skin reactions. If used on large body areas, they may lead to increased blood glucose (sugar) levels, changes in blood pressure, damage to bones, psychiatric problems, and changes in hormone levels (adrenal dysfunction).
FDA is unaware of any adverse events related to Skin-Cap aerosol spray products. Healthcare professionals and consumers should report adverse events or side effects associated with the use of this product to FDA’s MedWatch Safety Information and Adverse Event Reporting Program:
